■ 영문 제목 : Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027
|
 | ■ 상품코드 : IRTNTR73132-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 2월 ■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
Single User (1명 열람용) | USD2,500 ⇒환산₩3,375,000 | 견적의뢰/주문/질문 |
Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사는 세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모가 2022년부터 2027년 사이에 2,061.88백만 달러에 달하며, 예측 기간 중 연평균 7.96% 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 용도별 (병원 약국, 소매 약국, 온라인 약국, 기타) 분석, 제품별 (저분자, 생물 제제) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아 태평양, 기타 지역, 미국, 독일, 영국, 캐나다, 중국) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc. 와 같은 기업 정보를 포함하고 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모 : 용도별
- 병원 약국에서 사용되는 DLBCL 치료제의 시장 규모
- 소매 약국에서 사용되는 DLBCL 치료제의 시장 규모
- 온라인 약국에서 사용되는 DLBCL 치료제의 시장 규모
- 기타 용도에서 사용되는 DLBCL 치료제의 시장 규모
・세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모 : 제품별
- 저분자 치료제의 시장 규모
- 생물 제제의 시장 규모
・지역별 현황
- 북미의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 유럽의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 아시아 태평양의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 기타 지역의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 미국의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 독일의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 영국의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 캐나다의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
- 중국의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027Technavio has been monitoring the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market and is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the forecast period. Our report on the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.
Technavio’s diffuse large B-Cell Lymphoma (DLBCL) therapeutics market is segmented as below:
By Application
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
• Others
By Product
• Small molecules
• Biologics
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies technological advances as one of the prime reasons driving the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market covers the following areas:
• Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market sizing
• Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market forecast
• Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diffuse large B-Cell Lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 – 2021 ($ million)
o 4.2 Application Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
o 4.3 Product Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Application
o 6.1 Market segments
o Exhibit 30: Chart on Application – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Application – Market share 2022-2027 (%)
o 6.2 Comparison by Application
o Exhibit 32: Chart on Comparison by Application
o Exhibit 33: Data Table on Comparison by Application
o 6.3 Hospital pharmacy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o 6.4 Retail pharmacy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o 6.5 Online pharmacy – Market size and forecast 2022-2027
o Exhibit 42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
o 6.6 Others – Market size and forecast 2022-2027
o Exhibit 46: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.7 Market opportunity by Application
o Exhibit 50: Market opportunity by Application ($ million)
o Exhibit 51: Data Table on Market opportunity by Application ($ million)
• 7 Market Segmentation by Product
o 7.1 Market segments
o Exhibit 52: Chart on Product – Market share 2022-2027 (%)
o Exhibit 53: Data Table on Product – Market share 2022-2027 (%)
o 7.2 Comparison by Product
o Exhibit 54: Chart on Comparison by Product
o Exhibit 55: Data Table on Comparison by Product
o 7.3 Small molecules – Market size and forecast 2022-2027
o Exhibit 56: Chart on Small molecules – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Small molecules – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Small molecules – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Small molecules – Year-over-year growth 2022-2027 (%)
o 7.4 Biologics – Market size and forecast 2022-2027
o Exhibit 60: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Biologics – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Product
o Exhibit 64: Market opportunity by Product ($ million)
o Exhibit 65: Data Table on Market opportunity by Product ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2022-2027 (%)
o Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Canada – Market size and forecast 2022-2027
o Exhibit 99: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 103: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 115: AbbVie Inc. – Overview
o Exhibit 116: AbbVie Inc. – Product / Service
o Exhibit 117: AbbVie Inc. – Key news
o Exhibit 118: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 119: Amgen Inc. – Overview
o Exhibit 120: Amgen Inc. – Product / Service
o Exhibit 121: Amgen Inc. – Key offerings
o 12.5 Bayer AG
o Exhibit 122: Bayer AG – Overview
o Exhibit 123: Bayer AG – Business segments
o Exhibit 124: Bayer AG – Key news
o Exhibit 125: Bayer AG – Key offerings
o Exhibit 126: Bayer AG – Segment focus
o 12.6 BeiGene Ltd.
o Exhibit 127: BeiGene Ltd. – Overview
o Exhibit 128: BeiGene Ltd. – Business segments
o Exhibit 129: BeiGene Ltd. – Key offerings
o Exhibit 130: BeiGene Ltd. – Segment focus
o 12.7 Bristol Myers Squibb Co.
o Exhibit 131: Bristol Myers Squibb Co. – Overview
o Exhibit 132: Bristol Myers Squibb Co. – Product / Service
o Exhibit 133: Bristol Myers Squibb Co. – Key news
o Exhibit 134: Bristol Myers Squibb Co. – Key offerings
o 12.8 Celltrion Healthcare Co. Ltd.
o Exhibit 135: Celltrion Healthcare Co. Ltd. – Overview
o Exhibit 136: Celltrion Healthcare Co. Ltd. – Product / Service
o Exhibit 137: Celltrion Healthcare Co. Ltd. – Key offerings
o 12.9 CTI BioPharma Corp.
o Exhibit 138: CTI BioPharma Corp. – Overview
o Exhibit 139: CTI BioPharma Corp. – Product / Service
o Exhibit 140: CTI BioPharma Corp. – Key offerings
o 12.10 Erytech Pharma SA
o Exhibit 141: Erytech Pharma SA – Overview
o Exhibit 142: Erytech Pharma SA – Product / Service
o Exhibit 143: Erytech Pharma SA – Key offerings
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 144: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 145: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 146: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 147: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 148: F. Hoffmann La Roche Ltd. – Segment focus
o 12.12 GlaxoSmithKline Plc
o Exhibit 149: GlaxoSmithKline Plc – Overview
o Exhibit 150: GlaxoSmithKline Plc – Business segments
o Exhibit 151: GlaxoSmithKline Plc – Key offerings
o Exhibit 152: GlaxoSmithKline Plc – Segment focus
o 12.13 Johnson and Johnson
o Exhibit 153: Johnson and Johnson – Overview
o Exhibit 154: Johnson and Johnson – Business segments
o Exhibit 155: Johnson and Johnson – Key news
o Exhibit 156: Johnson and Johnson – Key offerings
o Exhibit 157: Johnson and Johnson – Segment focus
o 12.14 Merck and Co. Inc.
o Exhibit 158: Merck and Co. Inc. – Overview
o Exhibit 159: Merck and Co. Inc. – Business segments
o Exhibit 160: Merck and Co. Inc. – Key news
o Exhibit 161: Merck and Co. Inc. – Key offerings
o Exhibit 162: Merck and Co. Inc. – Segment focus
o 12.15 Novartis AG
o Exhibit 163: Novartis AG – Overview
o Exhibit 164: Novartis AG – Business segments
o Exhibit 165: Novartis AG – Key offerings
o Exhibit 166: Novartis AG – Segment focus
o 12.16 Pfizer Inc.
o Exhibit 167: Pfizer Inc. – Overview
o Exhibit 168: Pfizer Inc. – Product / Service
o Exhibit 169: Pfizer Inc. – Key news
o Exhibit 170: Pfizer Inc. – Key offerings
o 12.17 Spectrum Pharmaceuticals Inc.
o Exhibit 171: Spectrum Pharmaceuticals Inc. – Overview
o Exhibit 172: Spectrum Pharmaceuticals Inc. – Product / Service
o Exhibit 173: Spectrum Pharmaceuticals Inc. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 174: Inclusions checklist
o Exhibit 175: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 176: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 177: Research methodology
o Exhibit 178: Validation techniques employed for market sizing
o Exhibit 179: Information sources
o 13.5 List of abbreviations
o Exhibit 180: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Application
Exhibits6: Executive Summary – Chart on Market Segmentation by Product
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Application – Market share 2022-2027 (%)
Exhibits31: Data Table on Application – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Application
Exhibits33: Data Table on Comparison by Application
Exhibits34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits50: Market opportunity by Application ($ million)
Exhibits51: Data Table on Market opportunity by Application ($ million)
Exhibits52: Chart on Product – Market share 2022-2027 (%)
Exhibits53: Data Table on Product – Market share 2022-2027 (%)
Exhibits54: Chart on Comparison by Product
Exhibits55: Data Table on Comparison by Product
Exhibits56: Chart on Small molecules – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Small molecules – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Small molecules – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Small molecules – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Product ($ million)
Exhibits65: Data Table on Market opportunity by Product ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2022-2027 (%)
Exhibits68: Data Table on Market share by geography 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AbbVie Inc. – Overview
Exhibits116: AbbVie Inc. – Product / Service
Exhibits117: AbbVie Inc. – Key news
Exhibits118: AbbVie Inc. – Key offerings
Exhibits119: Amgen Inc. – Overview
Exhibits120: Amgen Inc. – Product / Service
Exhibits121: Amgen Inc. – Key offerings
Exhibits122: Bayer AG – Overview
Exhibits123: Bayer AG – Business segments
Exhibits124: Bayer AG – Key news
Exhibits125: Bayer AG – Key offerings
Exhibits126: Bayer AG – Segment focus
Exhibits127: BeiGene Ltd. – Overview
Exhibits128: BeiGene Ltd. – Business segments
Exhibits129: BeiGene Ltd. – Key offerings
Exhibits130: BeiGene Ltd. – Segment focus
Exhibits131: Bristol Myers Squibb Co. – Overview
Exhibits132: Bristol Myers Squibb Co. – Product / Service
Exhibits133: Bristol Myers Squibb Co. – Key news
Exhibits134: Bristol Myers Squibb Co. – Key offerings
Exhibits135: Celltrion Healthcare Co. Ltd. – Overview
Exhibits136: Celltrion Healthcare Co. Ltd. – Product / Service
Exhibits137: Celltrion Healthcare Co. Ltd. – Key offerings
Exhibits138: CTI BioPharma Corp. – Overview
Exhibits139: CTI BioPharma Corp. – Product / Service
Exhibits140: CTI BioPharma Corp. – Key offerings
Exhibits141: Erytech Pharma SA – Overview
Exhibits142: Erytech Pharma SA – Product / Service
Exhibits143: Erytech Pharma SA – Key offerings
Exhibits144: F. Hoffmann La Roche Ltd. – Overview
Exhibits145: F. Hoffmann La Roche Ltd. – Business segments
Exhibits146: F. Hoffmann La Roche Ltd. – Key news
Exhibits147: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits148: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits149: GlaxoSmithKline Plc – Overview
Exhibits150: GlaxoSmithKline Plc – Business segments
Exhibits151: GlaxoSmithKline Plc – Key offerings
Exhibits152: GlaxoSmithKline Plc – Segment focus
Exhibits153: Johnson and Johnson – Overview
Exhibits154: Johnson and Johnson – Business segments
Exhibits155: Johnson and Johnson – Key news
Exhibits156: Johnson and Johnson – Key offerings
Exhibits157: Johnson and Johnson – Segment focus
Exhibits158: Merck and Co. Inc. – Overview
Exhibits159: Merck and Co. Inc. – Business segments
Exhibits160: Merck and Co. Inc. – Key news
Exhibits161: Merck and Co. Inc. – Key offerings
Exhibits162: Merck and Co. Inc. – Segment focus
Exhibits163: Novartis AG – Overview
Exhibits164: Novartis AG – Business segments
Exhibits165: Novartis AG – Key offerings
Exhibits166: Novartis AG – Segment focus
Exhibits167: Pfizer Inc. – Overview
Exhibits168: Pfizer Inc. – Product / Service
Exhibits169: Pfizer Inc. – Key news
Exhibits170: Pfizer Inc. – Key offerings
Exhibits171: Spectrum Pharmaceuticals Inc. – Overview
Exhibits172: Spectrum Pharmaceuticals Inc. – Product / Service
Exhibits173: Spectrum Pharmaceuticals Inc. – Key offerings
Exhibits174: Inclusions checklist
Exhibits175: Exclusions checklist
Exhibits176: Currency conversion rates for US$
Exhibits177: Research methodology
Exhibits178: Validation techniques employed for market sizing
Exhibits179: Information sources
Exhibits180: List of abbreviations
|
※본 조사보고서 [세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 (2023년~2027년)] (코드 : IRTNTR73132-23) 판매에 관한 면책사항을 반드시 확인하세요. |
※본 조사보고서 [세계의 미만성 거대 B세포 림프종 (DLBCL) 치료제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!